Bristol-myers Squibb Compnay

Andres S Hernandez

Jeffrey A Robl

Jun Li

Joseph Anthony Tino

William N Washburn

William R Ewing

Saleem Ahmad

Bruce A Ellsworth

Jun Shi

Elizabeth Anne Jurica

Ximao Wu

Richard B Sulsky

Pratik Devasthale

James J Li

Guohua Zhao

Mark C Manfredi

Khehyong Ngu

Zhengxiang Gu

Wei Wang

Stephen P O'Connor

Zhenqiu Hong

Bin Chen

Stephen G Swartz

Zhenghua Wang

Stephen P O'CONNOR

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. 

Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them

MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein.

Azolopyrrolone melanin concentrating hormone receptor-1 antagonists

Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R, R, R, X, Xand Y are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.

Heterocyclic aromatic compounds useful as growth hormone secretagogues

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. where R, R, R, A, R, R, R, R5and Rare as defined herein.

Non-basic melanin concentrating hormone receptor-1 antagonists

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R, R, R, A, R, R, R, R5and Rare as defined herein.

Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structure including pharmaceutically acceptable salts thereof and all stereoisomers thereof, 

Heterocyclic aromatic compounds useful as growth hormone secreagogues

Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structureincluding pharmaceutically acceptable salts thereof and all stereoisomers thereof, wherein Xis heteroaryl, preferably,and R, R, R, Y, X, A, B, Z, R, R, R, Rand Rare as defined herein.

Heterocyclic aromatic compounds are provided which are useful in stimulating endogenous production or release of growth hormone and, in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The heterocyclic aromatic compounds have the structureincluding pharmaceutically acceptable salts thereof and all stereoisomers thereof,

Growing community of inventors

Lawrenceville, NJ, United States of America

Andres S Hernandez